Philip J. Mease, M.D.
Philip J. Mease, M.D. |
|||||
|
|||||
|
|||||
|
|
Home | Published Works | Center for Comprehensive Care | Curriculum Vitae | Links | Contact | |
|
|
|||||
|
|||||
Personal Data
| Birthplace | Roanoke, Virginia | Married, two children |
| Birthdate | October 4, 1951 | |
| Office Address |
Seattle Rheumatology Associates 1101 Madison Street, Suite 230 Seattle, WA 98104 |
Swedish Hospital Clinical Research Center 1120 Cherry Seattle, WA 98104 |
| Phone | (206) 386-2000 | |
| Fax | (206) 386-2083 | |
| pmease@u.washington.edu | ||
| Internet | http://faculty.washington.edu/pmease |
Education
| 1973-1977 | MD Stanford University Medical School, Stanford, California |
| 1969-1973 | BA Stanford University, Stanford, California |
| 1967-1969 | Phillips Exeter Academy, Exeter, New Hampshire |
Training
| 1981-1982 | Senior Fellow, Department of Internal Medicine, Division of Rheumatology and Division of Geriatrics, University of Washington, Seattle, WA |
| 1980-1981 | Chief Resident, Department of Medicine, University of Washington, Seattle, WA Senior Fellow, Division of Rheumatology, University of Washington School of Medicine, Seattle, WA |
| 1979-1980 | Senior Resident, Department of Internal Medicine, University of Washington, School of Medicine, Seattle, WA |
| 1978-1979 | Junior Resident, Department of Internal Medicine, University of Washington School of Medicine, Seattle, WA |
| 1977-1978 | Intern, Department of Internal Medicine, University of Washington School of Medicine, Seattle, WA |
Professional Experience
| 5/01-Present | Rheumatology and Internal Medicine, Seattle Rheumatology Associates, Seattle, WA |
| 5/01-Present | Investigator, Swedish Hospital Clinical Research Division, Seattle, WA |
| 1985-5/01 | Rheumatology and Internal Medicine, Minor &
James Medical, Seattle WA |
| 1996-12/00 | Medical Director, Division of Clinical Research,
Minor & James Medical, Seattle WA |
| 1989-Present | Medical/Research Consultant, Center for Comprehensive Care, Seattle, WA |
| 1995-12/01 | Medical/Research Consultant, Osteoporosis and
Bone Health Center, Minor & James Medical, Seattle, WA |
| 1982-Present | Clinical Professor, University of Washington, Seattle, WA |
| 1994-Present | Consultant, Clinical Development, MyoRx/EBOC Corporation |
| 1997-Present | Consultant, Clinical Development, Histatek Corporation |
| 1999-Present | Consultant, Clinical Development, Aventis Pharmaceuticals |
| 1999-Present | Consultant, Clinical Development, Centocor |
| 2000-Present | Consultant, Clinical Development, Immunex |
| 2000-Present | Consultant, Clinical Development, Zymogenetics |
| 2001-Present | Consultant, Clinical Development, Targeted Genetics |
| 2001-Present | Consultant, Clinical Development, Pharmacia |
| 2001-Present | Consultant, Clinical Development, Zorion |
| 2001-Present | Consultant, Clinical Development, Cypress Bioscience |
| 1983-1985 | Attending Physician, Providence Medical Center, Arthritis Center, Seattle, WA |
| 1982-1985 | Private Practice, Rheumatology and Internal Medicine, Seattle, WA |
Board Certification
| 1982 | American Board of Rheumatology |
| 1980 | American Board of Internal Medicine |
Licensure To Practice
| State of Washington License Number MD 00016710 |
Professional Organizations
| 1996 | American Society of Bone & Mineral Research |
| 1982 | King County Medical Society |
| 1982 | American College of Rheumatology |
| 1978 | American College of Physicians |
Hospital Appointments
| Swedish Medical Center |
| Providence Medical Center |
Teaching Activities
| Teaching Physician, Family Practice and Internal Medicine Residence Program, Swedish Medical Center, Seattle, WA |
| Teaching Physician, Family Practice and Internal Medicine Residence Program, Providence Medical Center, Seattle, WA |
| Clinical Professor, University of Washington Hospitals |
| Teaching Physician, Nurse Practitioner Program, Seattle University |
Advisory Boards
| 2001-Present | Immunex/Wyeth Ayerst, Psoriatic Arthritis and Psoriasis
Advisory Board |
| 2000-Present | Pfizer, Fibromyalgia Advisory Board |
| 1998-Present | Proctor & Gamble/Hoechst Marion Roussel, Alliance for Better Bone Health, Northwest Regional Expert Consultant Board |
| 1998-Present | Proctor & Gamble/Hoechst Marion Roussel, Alliance for Better Bone Health, National Primary Care Consultant Panel |
| 1998-Present | Immunex/Wyeth Ayerst, Patient Compliance Advisory Board |
Journal Review Boards
| Journal of Rheumatology |
Speaker's Bureaus
| Arthritis Foundation, Lupus Foundation, Sjogren’s Society, National Psoriasis Foundation, Wyeth Ayerst, Immunex, Merck, Searle, Pfizer, Aventis, Ortho McNeil, SmithKline Beecham, Genelab Technologies, Proctor & Gamble |
Community Activities
| 1999-Present | Director, Northwest Arthritis Institute (non-profit education and research foundation) |
| 1997-Present | Board, Lupus Foundation, Washington State Chapter |
| 1988-Present | Medical Advisory Board, Lupus Foundation, Washington State Chapter |
| 1994-1996 | Professional Education Committee, Arthritis Foundation, Washington
State Chapter |
| 1990-1996 | Coach, Seattle Youth Soccer Association |
| 1989-1993 | Executive Committee, Arthritis Foundation, Washington State Chapter |
| 1989-1993 | Chair, Education Committee, Arthritis Foundation , Washington State Chapter |
| 1989-1993 | Board, Arthritis Foundation, Washington State Chapter |
Honors & Awards
| 2000 | Recognized in The Best Doctors in Western Washington |
| 2000 | Lifetime Member, National Registry of Who’s Who |
| 1993 | Medical Communicator Award of the American College of Rheumatology Awarded annually to the physician who most effectively and dynamically presents Rheumatology subjects to the public. |
| 1992 | Recognized in The Best Doctors in America |
| 1992 | Recognized in The Best Doctors in Western Washington |
Bibliography
Book Chapters
Mease PJ: Rheumatologic Issues. in Agostini R (ed.) Medical and Orthopedic Issues of Active and Athletic Women. Hanley & Belfus, Philadelphia 1994.
Mease PJ: Culture variations in health care. Transcultural Study Guide, Volunteers in Asia Press, 1973.
Journal Articles
Mease PJ, Ochs HD, Wedgewood RJ: Successful treatment of ECHO-virus meningoencephalitis and myositis- fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. New Engl J Med 304: 1278-1281, 1981.
Fretwell MD, Pearlman RA, Vestal RE, Mease PJ, Hazard WR: Fever and delirium in three elderly patients. A discussion of possible cimetidine toxicity, cimetidine pharmacology, and the application of decision analysis to cimetidine therapy. Medical Grand Rounds 1:223-238, 1982.
Mease PJ, Ellsworth JG, Killen PD, Willkens RF: Zomepirac, Interstitial Nephritis, and Renal Failure. Ann Int Med 97:454, 1982.
Mease PJ, Willkens RF: Treatment of Acute Gout with Oxaprozin. Sem Arth Rheum 15 (Suppl 2): 86-89, 1986.
Culpepper RC, Williams RG, Mease PJ, et al. Eosinophilia Myalgia Syndrome: Investigation of Washington Cases. Wash Pub Health 16-18, Winter 1991.
Culpepper RC, Williams RG, Mease PJ, et al. Natural History of the Eosinophilia Myalgia Syndrome. Ann Int Med 115: 437-442, 1991.
Katon WJ, Buchwald DJ, Simon GE, Russo JE, Mease PJ: Psychiatric Illness in patients with chronic fatigue and those with rheumatoid arthritis. J Gen Int Med 6:227-285, 1991.
Buchwald DJ, Blair J, Mease PJ: Treatment of Chronic Fatigue Syndrome with Acupuncture. Intl J Clinical Acupuncture 2: 231-236, 1991.
Hertzman P, Kaufman L, Love L, Mease P, et al. Eosinophilia Myalgia Syndrome: Guidelines for Patient Care. J Rheum 22: 161-163, 1995.
Hertzman P, Clauw D, Kaufman L, Vargas J, Silver R, Thacker H, Mease P, Espinoza L, Pincus T: The Eosinophilia-Myalgia Syndrome: Status of 205 Patients and Results of Treatment 2 Years after Onset. Ann Intern Med 1995;122:851-855.
Wolfe F, Allen M, Bennett RM, Bombardier C, Mease P, et al. The Fibromyalgia Syndrome: A Consensus Report on Fibromyalgia and Disability. J Rheum 1996;23:534-539.
Moreland LW, . . . Mease PJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Internal Medicine 130:478-486, 1999
Moreland LW, . . . Mease PJ, et al. Long-term treatment of rheumatoid arthritis with Etanercept (Tumor Necrosis Factor Receptor p75 Fc Fusion Protein, ENbrEL™). Lancet, 1999.
Mease PJ, Goffe B, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385-390, 2000.
Mease PJ. Etanercept in the management of psoriatic arthritis and psoriasis. J of Musculoskeletal Medicine
Supplement, S45-S49 May 2001.Mease PJ. Cytokine blockers in psoriatic arthritis. Annals of Rheumatic Disease, in press
Abstracts
Ochs HD, Mease PJ, Wedgwood RJ, Rischer SH: Generalized Echo-11virus infection in X-linked agammaglobulinemia: Successful treatment with large doses of modified gammaglobulin given intravenously.
Primary Immunodeficiencies, Seligmann, Hitig (editor). INSERUM Symposium No. 16, The Netherlands: Elsevier, North Holland Biomedical Press, 513-514, 1980.Mease PJ, Ochs HD: Successful treatment of the dermatomyositis/meningoencephalitis syndrome in X-linked agammaglobulinemia with intravenous immune globulin. Clinical Research 29 (No.1): 92A, 1981.
Mease PJ, Ochs HD, Wedgewood RJ: Successful treatment of the dermatomyositis/meningoencephalitis syndrome in X-linked agammaglobulinemia with intravenous immune globulin. Clinical Research 29 (No. 2):
372A, 1981.Mease PJ, Ochs HD, Wedgwood RJ: Successful treatment of the ECHO-virus induced dermatomyositis/meningoencephalitis syndrome in X-linked agammaglobulinemia with intravenous immune globulin. 15th International Congress of Rheumatology, Paris, France, June, 1981.
Bowden RA, Mease PJ: Human Herpes Virus 6 (HHV6) infection in a patient with undifferentiated autoimmune
disease; evidence for clinical infection? 28th ICAAC, Los Angeles, California, October 1988.Culpepper RC, Williams RG, Mease PJ, et at. Eosinophilia Myalgia Syndrome (EMS): Epidemiologic
features, progression of disease, and therapeutic approaches. Arth Rheum 33(No. 9): 518, 1990.Townes B, Mease P, Claypoole K, et al. Neurocognitive dysfunctioning in eosinophilia myalgia syndrome.
Arth Rheum 35 (No. 9) (Supplement): S67, 1992.Blair J, Mease P, Buchwald D, et al. The use of acupuncture as an intervention in a fibromyalgia and chronic fatigue self-management program. J. Musculoskeletal Pain 3 (No. 1)(Supplement): 90, 1995.
Mease PJ, Driscoll P, Uslan D, et al. Multidisciplinary self-management and treatment program for patients with fibromyalgia and chronic fatigue syndrome. Arth Rheum 38 (No. 9)(Supplement): S271, 1995.
Mease PJ, Overman SS, Green DJ. Clinical symptoms/signs and laboratory features in symptomatic patients with silicone breast implants. Arth Rheum 38 (No. 9) (Supplement): S324, 1995.
Weinblatt M, Moreland LW, Schiff M,…Mease P, et al. Long-term and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc Enbrel™), Arth Rheum 1997;40 (Supp.9):S126
Baumgartner SW,…Mease P, et al. Phase III and longterm treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc). Rheumatology in Europe, 1997.
Moreland LW,…Mease PJ, et al. Long-term treatment of rheumatoid arthritis (RA) with p75 TNF receptor (TNFR:Fc; Enbrel). 19th International League of Associations for Rheumatology, 1997.
Schiff MH, Moreland LW, Baumgartner SW,…Mease P, et al. Quality of life (QOL) and laboratory measures in a phase III trial of TNF-receptor (p75):Fc fusion protein (TNFR:Fc; Enbrel™) in DMARD failing rheumatoid arthritis. Intl Soc Rheum Therapy, 1998.
Schiff MH, Moreland LW, Baumgartner SW,…Mease P, et al. TNF receptor (p75):Fc Fusion Protein (TNFR:Fc: Enbrel™) results in improvement in clinical laboratory parameters in patients with rheumatoid arthritis (RA). Intl Soc Rheum Therapy, 1998.
Ehrich E, … Mease P, et al. The effect of MK-0966 (Vioxx™), a cox-2 specific inhibitor, on health related quality of life in osteoarthritis patients. EULAR, 1998..
Baumgartner SW,… Mease PJ, et al. Response of elderly patients to TNF receptor p75 FC fusion protein TNFR:Fc; Enbrel™). Arth Rheum 41 (Supp. 9): 559, 1998.
Moreland LW, … Mease PJ, et al. Optimal dose of TNF receptor p75 FC fusion protein (TNFR:Fc; Enbrel™).
Arth Rheum 41 (Supp. 9): 559, 1998.Moreland LW, … Mease PJ, et al. Long term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc; Enbrel™) in DMARD refractory rheumatoid arthritis (RA). Arth Rheum 41 (Supp. 9): S364. 1998.
Moreland LW,… Mease PJ, et al. Long-term treatment of rheumatoid arthritis (RA) with TNF receptor p75 Fc fusion protein (TNFR:Fc; Enbrel™). J Investig Med, 1998.
Moreland LW,…Mease PJ, et al. Long-term treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc; Enbrel). EULAR, 1998.
Moreland LW,…Mease PJ, et al. Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor p75 fusion protein (TNFR:Fc; Enbrel). J Investig Med, 1998.
Moreland LW,…Mease PJ, et al. Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor fusion protein (TNFR:Fc; Enbrel). EULAR, 1998.
Moreland LW,…Mease PJ, et al. Long-term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc; Enbrel) in DMARD refractory rheumatoid arthritis (RA). Ann Rheum Dis, 1998.
Mease PJ, Goffe B, Metz J, Vanderstoep A. Etanercept in patients with psoriatic arthritis and psoriasis. Arth Rheum 42 (Supp.), 1999.
Mease PJ, Goffe B, Metz J, Vanderstoep A. Phase II trial of Enbrel (Etanercept) in patients with psoriasis and psoriatic arthritis (PsA). American Academy of Allergy Asthma & Immunology, 2000.
Mease PJ, Goffe B, Metz J, Vanderstoep A. Etanercept in patients with psoriatic arthritis and psoriasis. American Academy of Dermatology, San Francisco, CA. 3/00.
Mease PJ, Merrill J, Lahita R, et al. GL701 (Dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Autoimmunity: 2000 and Beyond. Eighth International Conference on Lymphocyte Activation and Immune Regulation, Newport Beach, CA, 2/00.
Mease PJ, Merrill J, Lahita R, et al. GL701 (Prasterone, Dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erytematosus. Endocrine Society, 2000.
Mease PJ, Ginzler EM, Gluck OS. GL701 (prasterone, dehydroepiandrosterone) improves bone density in steroid-treated female lupus patients. Am Soc Bone Min Research, 2000.
Mease PJ, Goffe B, Metz J, et al. Enbrel (Etanercept) in patients with psoriatic arthritis and psoriasis. Arth Rheum 43 (Suppl 9):S403, 2000.
Mease PJ, Merrill JT, Lahita RG, et al. GL701 (Prasterone, Dehydroepiandrosterone) improves systemic lupus erythematosus. Arth Rheum 43 (Suppl 9):S271, 2000.
Mease PJ, Ginzler EM, Gluck OS, et al. Improvement in bone mineral density in steroid-treated SLE patients during treatment with GL701 (Prasterone, Dehydroepiandrosterone). Arth Rheum 43 (Suppl 9):S206, 2000.
Fraser PA, …Mease PJ, et al. TNF alpha-308 rather than HLA-DRB1 alleles are markers of early response to etanercept in Still’s disease in the adult. Arth Rheum 43 (Suppl 9):S228, 2000.
Weinblatt ME, …Mease PJ, et al. Etanercept in Still’s disease in the adult. Arth Rheum 43 (Suppl 9):S391, 2000.
Schiff M, Mease PJ, Weinblatt M, et al. Randomized controlled trial of 25 Mg vs. 50 Mg Enbrel (Etanercept) twice weekly in rheumatoid arthritis (RA). Arth Rheum 43 (Suppl 9):S391, 2000.
Mease PJ, Goffe B, Metz J, et al. Etanercept in patients with psoriatic arthritis and psoriasis. American Academy of
Dermatology, 55th Annual Meeting. Washington, DC. 3/2-7/01.Mease PJ, Gofe B, Metz J, et al. Etanercept in patients with psoriatic arthritis and psoriasis. EULAR, Prague, 6/01.
Mease PJ, Goffe B, Metz J, et al. Etanercept in patients with psoriatic arthritis and psoriasis. International Symposium on Psoriasis and European Congress on Psoriasis. San Francisco, CA 6/01.
Mease PJ, Goffe B, Metz J, et. al. Etanercept in patients with psoriatic arthritis and psoriasis. In Year Book of Rheumatology, Arthritis, and Musculoskeletal Disease, ed. Panush R, Mosby-Year Book, St. Louis, in press.
Mease PJ, Goffe B, Metz J, et. al. Etanercept in patients with psoriatic arthritis and psoriasis. In Year Book of Dermatology, Mosby-Year Book, St. Louis, in press.
Newsletters & Periodical Articles
1998-Present Quarterly Q & A column, Lupus Foundation Newsletter, Washington State Chapter. 1995 DHEA and Lupus, Newsletter of the American Lupus Society - Seattle/Bellevue Chapter. 1996 Rheumatological Disorders Associated with Celiac Sprue and Dermatitis Herpetiformis. Newsletter of the Gluten Intolerance Group of North America.
Research Activities
2001 |
- IL-1 modulator in RA (Principal Investigator)
(Immunex) - Raloxifene v. Alendronate in osteoporosis (Principal Investigator) (Lilly) - Enbrel in psoriatic arthritis and psoriasis (Principal Investigator/protocol development) (Immunex) - Remicade in RA - the iRAMT trial (Principal Investigator) (Centocor) - Duloxitene in fibromyalgia (Principal Investigator) (Lilly) - Enbrel in RA - longterm safety and efficacy (Principal Investigator) (Immunex) - Choices - osteoporosis patient education research (Prinicipal Investigator) (Procter&Gamble/Aventis) - Rheumatoid joint tissue sampling for genetic therapy development (Principal Investigator) (Targeted Genetics) - RA, Lupus, Psoriasis patient blood sampling for drug development (Principal Investigator) (Zymogenetics) |
2000 |
- IL1RA +/- Enbrel in rheumatoid arthritis (Principal
Investigator) (Amgen) - Anti- DNA antibody treatment in lupus nephritis (Principal Investigator) (La Jolla Pharmaceuticals) - Psoriais skin transplantation to SCID mice (Principal Investigator/protocol development) (Zymogenetics) - PTH in osteoporosis (Principal Investigator) (Allelix) - Pregabalin in diabetic neuropathy (Principal Investigator) (Pfizer) - Enbrel in psoriatic arthritis and psoriasis (Principal Investigator/protocol development) (Immunex) - Enbrel in RA with co- morbid diseases (Principal Investigator) (Immunex) - Remicade in RA (Principal Investigator) (Centocor) - Anti- TNF (pegylated) in RA (Sub- Investigator) (Amgen) - Insulin growth factor 1 in OA (Principal Investigator) (Chiron) - Prosorba column in RA (Sub- Investigator) (Cypress Bioscience) - Lupus patient blood sampling (Principal Investigator) (Cellpath) - Autoimmune disease patient blood sampling (Principal Investigator/protocol development) (Zymogenetics) - Enbrel in RA - long term safety and efficacy (Principal Investigator) (Immunex) - Valdecoxib in OA and RA (Principal Investigator) (Searle) - Pregabalin in Fibromyalgia (Principal Investigator) (Parke- Davis) - Vioxx in RA (Principal Investigator) (Merck) |
1999 |
- Enbrel™ in psoriatic arthritis and psoriasis
(Principal Investigator/protocol development/FDA submission with Immunex
support) - Enbrel in RA: 25 vs. 50 mg dosing (Principal Investigator) (Immunex) - Anti-TNF (pegylated) in RA (Sub-Investigator) (Amgen) - Risedronate - weekly vs. daily dosing in Osteoporosis (Principal Investigator) (P&G/HMR) - Pregabalin in Fibromyalgia (Principal Investigator) (Parke-Davis) - Valdecoxib in OA and RA (Principal Investigator) (Searle) - Celebrex (Cox-2 NSAID) Gastrotoxicity (OA/RA) (Principal Investigator) (Searle) - D2E7(anti-TNF)in RA (Sub-Investigator) (Knoll) - DHEA in Lupus (Principal Investigator) (Genelabs) - Parathyroid Hormone in Osteoporosis (Principal Investigator) (Lilly) - Idoxifene in Postmenopausal Women with Vasomotor Symptoms (Principal Investigator) (SmithKline Beecham) - Idoxifene in Osteoporotic and Osteopenic Women (Principal Investigator) (SmithKline Beecham) - Anti-TNF in RA (Sub-Investigator) (Roche) - Enbrel in RA (Principal Investigator) (Immunex) - UCLA RA Treatment Outcome Study - NSAID Gastrotoxicity (Principal Investigator) (Searle) - Vioxx in OA/RA (Sub-Investigator) (Merck) - Colloral in RA (Principal Investigator) (Autoimmune) - Bay 12-9566 (metalloproteinase inhibitor) in OA (Principal Investigator) (Bayer) |
1998 |
-Enbrel™ in psoriatic arthritis and psoriasis (Principal Investigator/protocol
development/FDA submission with Immunex support) |
1997 |
- DHEA in Lupus (Principal Investigator) (Genelabs) |
1996 |
- TNFR in RA (Principal Investigator) (Immunex) |
1995 |
- Cox-2 Anti-inflammatory (Principal Investigator) (Merck) |
1994 |
- sTNFR-IgG in RA (Roche) |
1992-1993 |
- Silicone related disorders |
1989-1991 |
- Eosinophilia Myalgia Syndrome (EMS) |
Invited Presentations & Symposia
2001 |
-“Osteoporosis” - Physician CE, Seattle,
WA -“Osteoporosis - Current Diagnosis and Treatment” Physician CE, Kirkland, WA -“Osteoporosis” Physician CE, Seattle, WA -“Cytokine blockers in Psoriatic Arthritis” Targeted Therapies Symposium, Nassau, Bahamas -“Arthritis” Community Education Symposium, Swedish Hospital, Seattle, WA -“Osteoporosis for gastroenterologists” Gastroenterology symposium, Everett, WA -“Anti-TNF Therapy in the Treatment of Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Wegener’s Granulomatosis, and CHF” Rheumatology Rounds, Yale University, New Haven, Conn -Ibid, Rheumatology Rounds, University of Connecticut -Ibid, Targeted Genetics, Seattle, WA -“So you have a touch of… Management Approach to Difficult-to-Define Rheumatic Disease Presentations” Family Practice Day, Swedish Hospital, Seattle, WA -“Psoriatic Arthritis and Psoriasis - Current Review of Treatment Options” Grand Rounds, St. Vincent Hospital, Portland, Oregon -“Enbrel in the Treatment of Non-RA Rheumatic Diseases” Rheumatology Symposium, Spokane, WA -“Osteoporosis - Update on Diagnosis and Treatment” Grand Rounds, Allenmore Hospital, Tacoma, WA |
2000 |
-“Etanercept in the Treatment of Psoriatic
Arthritis and Psoriasis - A Clinical Update”, Post-ACR CME Symposium Philadelphis, Pennsylvania -“Osteoporosis in the US and in Washington State; Case Study Review”, Medical Consultant Review, Seattle, WA -“New Developments in the Clinical Use of COX-2 Inhibitors”, Medical Consultant Review, Seattle, WA -“New Developments in Rheumatic Disease Pharmacotherapy”, Rheumatology Symposium, Seattle, WA -“Newer Uses of Enbrel in Rheumatic Diseases”, Houston Rheumatology Association, Houston, Texas -Ibid, Virginia Rheumatology Association, Norfolk, Virginia -Ibid, Las Vegas Rheumatology Association, Las Vegas, Nevada -“Enbrel in the Treatment of Psoriatic Arthritis and Psoriasis”, Dermatology Rounds, OHSU, Portland, Oregon - Ibid, Greater Chicago Rheumatology Association, Chicago, Illinois - Ibid, Rush-Presbyterian Rheumatology/Dermatology Rounds, Chicago, Illinois -Ibid, Kaiser-Permanente Rheumatology Group, Los Angeles, California -“New Developments in the Treatment of Osteoporosis”, Physician CE, Chuckanut, WA -“Arthritis and the COX2 InhibitorsWhat Have We Learned to Date?”, Physician CE, Federal Way, WA -“Osteoporosis, Lupus, Antiphospholipid Antibody Syndrome” Family Practice Program, Swedish Hospital, Seattle -“Enbrel in the Treatment of Psoriatic Arthritis, Psoriasis, Wegener’s Granulomatosis, and Early RA” Northern California Rheumatology Association, San Mateo, CA. - “New Developments in the Diagnosis and Treatment of Osteoporosis”, Physician CE, Seattle, WA. - Ibid, Physician CE, Kirkland, WA. - “Psoriatic Arthritis” National Psoriasis Foundation Symposium, Seattle, WA. -“Enbrel in the Treatment of Psoriatic Arthritis and Psoriasis” Rheumatology CE, Sacramento , CA. - Ibid. EULAR symposium, Nice, France. - Ibid. Rheumatology CE, Phoenix, Ariz. - Ibid. Medical Grand Rounds, Maricopa County Hospital, Phoenix, Ariz. - Ibid. Medical Grand Rounds, Beth Israel Hospital, NY, NY. - Ibid. Rheumatology CE, Cabrini Hospital, NY, NY. - Ibid. Rheumatology CE, Columbia University Medical Center, NY, NY. - Ibid. Rheumatology CE, Montefiore Medical Center, NY, NY. - Ibid. Rheumatology CE, Brooklyn VA Hospital, NY, NY. - Ibid. Rheumatology CE, Mt. Sinai Medical Center, NY, NY. - Ibid. Rheumatology CE, NY, NY. - Ibid. Rheumatology CE, Portland, Ore. - Ibid. Immunex Regional Consultant Meeting, SF, CA. - Ibid. Seattle Dermatology Academy, Seattle, WA. - Ibid. Immunex Investigator Meeting, Orlando, Fla. - “Joint assessment in psoriatic arthritis” Immunex Investigator Meeting, Orlando, Fla. - “Arthritis” Community Education Program, Swedish Hospital, Seattle, WA. - “Rheumatoid Arthritis and Lupus” Family Practice Education Program, Swedish Hospital, Seattle, WA. -“Enbrel in the Treatment of Psoriatic Arthritis and Psoriasis” Rheumatology for Primary Care, Mt. Batchelor, Oregon. - Ibid. Rheumatology CE, Georgetown University, Washington, D.C. - Ibid. Rheumatology CE, Washington Hospital, Washington., D.C. -“Treatment of Psoriatic Arthritis” National Teleconferences (series of 8) sponsored by the University of Wisconsin Medical School. -“Enbrel in the Treatment of Psoriatic Arthritis and Psoriasis” Rheumatology CE, Tacoma, Wa. -“Enbrel in the Treatment of Early RA, Psoriatic Arthritis and Psoriasis, and Long-Term Safety and Efficacy” Rheumatology CE, Seattle, WA. -“Enbrel in the Treatment of Psoriatic Arthritis and Psoriasis” Rheumatology CE, Denver, Colo. - Ibid. Rheumatology CE, Colorado Springs, Colo. - Ibid. Rheumatology CE, Dallas, Texas. - Ibid. Rheumatology CE, Oklahoma City, Oklahoma. -“Diagnosis and Treatment of Lupus” Community Education Program, Swedish Hospital, Seattle, WA. |
1999 |
-“Use of Enbrel in Other Rheumatic Diseases”
Immunex Faculty Briefing, Chicago, Ill. -“Practical Approach to Treatment of Arthritis Pain in the Elderly” Geriatric Pain Symposium, Seattle, WA. - “Clinical Use of Enbrel in Rheumatoid Arthritis” Immunex Masters of Rheumatology Program, Seattle, WA. -“Safety and Efficacy of Enbrel in Rheumatoid Arthritis, Controlled and Long-term Trials” Immunex Regional Consultant Meeting, Newport Beach, CA. - “Safety and Efficacy of Enbrel in Rheumatoid Arthritis, Controlled and Long-Term Trials” Immunex Regional Consultant Meeting, Orlando, Florida. -“What is Integrational Medicine?” Panel discussion. International Symposium on Integrational Medicine, Seattle, WA. - “Development of a Multidisciplinary Program for the Treatment of Fibromyalgia” International Symposium on Integrational Medicine, Seattle, WA. - “Advances in the Treatment of Osteoarthritis and Rheumatoid Arthritis.” Minor & James Medical, Seattle, WA. - “New Developments in Rheumatic Disease Pharmacotherapy.” CME Family Practice Programs, Swedish Hospital Medical Center and Providence Hospital, Seattle, WA. - “New Developments in Arthritis.” Community Education Program, Swedish Hospital Medical Center, Seattle, WA - “Update in Rheumatic Disease Pharmacotherapy” Grand Rounds, Swedish Hospital, Seattle, WA. - “New Developments in Pharmacotherapy of Arthritis and Rheumatic Disease.” Nurse Practitioner Association Symposium. Northwest Hospital, Seattle, WA |
1998 |
-“Update in Pharmacotherapy of Arthritis
and Rheumatic Disease.” Grand Rounds, Swedish Hospital Medical Center,
Seattle, WA - “What is Lupus?” Community Education Program. Swedish Hospital Medical Center, Seattle, WA - “Update in Rheumatic Disease Pharmacotherapy.” Physician CME , Seattle, WA - “Update in Rheumatic Disease Pharmacotherapy.” Pierce County Pharmacists Association, Tacoma, WA. - “Rheumatoid Arthritis and Lupus.” Family Practice Program, Swedish Hospital Medical Center, Seattle, WA |
1997 |
- “Update on Trends in Pain Management-Current Approaches to the
Treatment of Pain |
1996 |
- “Psoriatic Arthritis.” National Psoriasis Foundation Annual
Meeting, Seattle, WA |
1995 |
- “Rheumatology.” Family Practice Residency Program,
Providence Hospital, Seattle, WA. |
1994 |
-“Fibromyalgia and Chronic Fatigue Syndrome.” Expert Consensus
Conference, Physical Medicine |
1993 |
- “Multidisciplinary Treatment of Arthritis.” Arthritis Foundation
Symposium, Seattle, WA |
1992 |
- “Fibromyalgia and Chronic Fatigue Syndrome.” Rheumatology
Symposium, University of Washington, Seattle, WA |
1991 |
- “Fibromyalgia and Chronic Fatigue Syndrome.” UW Rheumatology
Symposium, Seattle, WA |
1990 |
- “FM/CFS.” CME Symposium, UW OB/GYN, Seattle, WA |
1989 |
- “FM/CFS.” Arthritis Day, Seattle, WA |
1988 |
- “Arthritis.” Arthritis Foundation Speakers Bureau, Seattle, WA |
1987 |
- “Arthritis.” Arthritis Foundation Speakers Bureau, Seattle, WA |
1986 |
- “Arthritis.” Arthritis Foundation Speakers Bureau, Seattle, WA |
1985 |
- - “Soft Tissue Rheumatism.” Cabrini Hospital, Seattle, WA |
1984 |
- “Crystalline Arthritis.” Cabrini Hospital, Seattle,
WA - “Raynaud’s.” Providence Hospital, Seattle, WA - “Arthritis.” Arthritis Foundation Speakers Bureau, Seattle, WA |
1983 |
- “Raynaud’s.” Cabrini Hospital, Seattle, WA |